Ryvu Therapeutics SA
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
RVU120 Rollover Study
- Conditions
- Advanced Solid TumorsAcute Myeloid Leukaemia (AML)High-risk Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 10
- Registration Number
- NCT06987058
- Locations
- 🇵🇱
Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 178
- Registration Number
- NCT06534437
- Locations
- 🇫🇷
Centre Hospitalier Le Mans, Le Mans, France
🇫🇷CHU de Limoges - CHU Dupuytren, Limoges CEDEX 1, France
🇫🇷Hospices Civils De Lyon - Hôpital Lyon Sud, Lyon, France
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 230
- Registration Number
- NCT06397313
- Locations
- 🇮🇹
Policlinico Sant'Orsola-Malpighi, Bologna, Italy
🇮🇹Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
🇮🇹Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
- Conditions
- High-risk Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 94
- Registration Number
- NCT06268574
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Grenoble Alpes, la Tronche, France
🇫🇷Centre Hospitalier Le Mans, le Mans, France
🇫🇷Centre Hospitalier Universitaire de Lille (CHU Lille), Lille, France
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 98
- Registration Number
- NCT06191263
- Locations
- 🇮🇹
AUSL Romagna - Ospedale S.M. Delle Croci, Ravenna, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, Italy
🇵🇱PRATIA Onkologia Katowice, Katowice, Poland
- Prev
- 1
- 2
- Next